MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-13-2026
Savara Total Liabilities 2011-2026 | SVRA
Annual Total Liabilities Savara
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.3 M | 41.4 M | 37.2 M | 32 M | 32.1 M | 33.4 M | 34.5 M | 44.1 M | 40.3 M | 8.16 M | 30.3 M | 11.8 M | 7.44 M | 5.18 M | 5.08 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50.3 M | 5.08 M | 27.6 M |
Quarterly Total Liabilities Savara
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.5 M | 43.3 M | 41.5 M | 41.4 M | 39.5 M | 37.9 M | 36.4 M | 37.2 M | 35.5 M | 32.1 M | 31.1 M | 32 M | 31.2 M | 29.7 M | 29.7 M | 32.1 M | 32 M | 31.1 M | 32.5 M | 33.4 M | 33.4 M | 33.4 M | 33.4 M | 34.5 M | 34.5 M | 34.5 M | 34.5 M | 44.1 M | 44.1 M | 44.1 M | 44.1 M | 40.3 M | 40.3 M | 40.3 M | 40.3 M | 20.9 M | 20.9 M | 20.9 M | 8.16 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 7.44 M | 7.44 M | 7.44 M | 7.44 M | 5.18 M | 5.18 M | 5.18 M | 5.18 M | 5.08 M | 5.08 M | 5.08 M | 5.08 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 46.5 M | 5.08 M | 27 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Heron Therapeutics
HRTX
|
242 M | $ 0.8 | 2.7 % | $ 133 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Altimmune
ALT
|
55 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
1.47 B | $ 218.06 | -1.72 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Incyte Corporation
INCY
|
1.79 B | $ 90.45 | -0.36 % | $ 17.7 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Inovio Pharmaceuticals
INO
|
53.6 M | $ 1.61 | 1.9 % | $ 35.7 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Inventiva S.A.
IVA
|
226 M | $ 6.08 | 5.19 % | $ 138 M | France |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
39.6 M | $ 12.84 | 0.78 % | $ 774 M | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
KalVista Pharmaceuticals
KALV
|
8.78 M | $ 16.6 | -2.35 % | $ 824 M | Britain |
 |
Kamada Ltd.
KMDA
|
32 M | $ 8.2 | -0.61 % | $ 260 M | Israel |
 |
Calithera Biosciences
CALA
|
15.7 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
68.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
Karyopharm Therapeutics
KPTI
|
350 M | $ 6.66 | -12.71 % | $ 812 K | USA |
 |
Keros Therapeutics
KROS
|
34.9 M | $ 11.24 | 2.55 % | $ 418 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
752 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Longeveron
LGVN
|
4.59 M | $ 0.95 | -2.71 % | $ 16.7 B | USA |
 |
Denali Therapeutics
DNLI
|
144 M | $ 21.09 | 4.56 % | $ 3.47 B | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
38.4 M | $ 4.42 | 4.25 % | $ 734 M | Canada |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |